Latest Breaking News On - வலேரியா மீனவர் - Page 6 : comparemela.com
Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
NOXXON Pharma N V : NOXXON Pharma: Data Safety Monitoring Board Confirms Safety and Validates Recruitment of Last Patients in Final High-Dose Cohort of NOX-A12 in Phase 1/2 Brain Cancer Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NOXXON Pharma N.V.: NOXXON Enrolls First Patient in the High Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer
NOXXON Pharma N.V.
(Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the enrollment and first week of treatment of the first patient in the third, high dose cohort of the Phase 1/2 clinical trial. The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients who would not benefit clinically from treatment with standard chemotherapy.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update
February 12, 2021 GMT
LYON, France (BUSINESS WIRE) Feb 12, 2021
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the twelve months ended December 31, 2020 and provided a corporate update.
ADVERTISEMENT
“Despite the challenges posed by the COVID-19 pandemic, Poxel ended 2020 on a strong note, having accomplished several important corporate and clinical milestones and positioning the Company for an exciting 2021. We continued working closely with our partner Sumitomo Dainippon Pharma to further advance the review of the Japanese New Drug Application for Imeglimin follo
Press release content from Business Wire. The AP news staff was not involved in its creation.
NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board
February 8, 2021 GMT
Regulatory News:
NOXXON Pharma N.V.
(Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of four leading pancreatic cancer experts to its Scientific Advisory Board (SAB). Led by the newly appointed Chair, Dr. Jose Saro, the SAB will provide strategic and scientific counsel to NOXXON’s clinical programs in this indication.
“These prominent research leaders bring long-standing clinical expertise, cutting-edge scientific knowledge, and a track record of successfully developing new drugs to treat this devastating disease. They fully understand the challenges of developing new drugs for pancreas cancer where the tumor microenvironment plays a large role in resisting ant
vimarsana © 2020. All Rights Reserved.